Page 89 - Read Online
P. 89
Page 20 of 22 Ma et al. Hepatoma Res. 2026;12:43
13. Sangro B, Kudo M, Erinjeri JP, et al. ; EMERALD-1 Investigators. Durvalumab with or without bevacizumab with transarterial
chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3
study. Lancet. 2025;405:216-32. DOI PubMed PMC
14. Kudo M, Ren Z, Guo Y, et al. ; LEAP-012 investigators. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab
versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind,
phase 3 study. Lancet. 2025;405:203-15. DOI PubMed
15. Zhu HD, Li HL, Huang MS, et al. ; CHANCE001 Investigators. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular
targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023;8:58. DOI PubMed PMC
16. Jin ZC, Chen JJ, Zhu XL, et al. ; CHANCE2201 Investigators. Immune checkpoint inhibitors and anti-vascular endothelial growth factor
antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular
carcinoma (CHANCE2201): a target trial emulation study. EClinicalMedicine. 2024;72:102622. DOI PubMed PMC
17. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular
carcinoma. Hepatology. 2002;35:1164-71. DOI PubMed
18. Llovet JM, Real MI, Montaña X, et al. ; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic
treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-9. DOI PubMed
19. China NHCotPsRo. Guideline for the diagnosis and treatment of primary liver cancer (2024 edition). J Multidiscip Cancer Manag
2024;10:17-68. (in Chinese) Available from https://www.nhc.gov.cn/yzygj/c100068/202404/b12cab9adae7424493cd2d387f018367.shtm
l [accessed 29 July 2026].
20. Raoul JL, Gilabert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver
Cancer. 2014;3:119-24. DOI PubMed PMC
21. Kudo M, Matsui O, Izumi N, et al. ; Liver Cancer Study Group of Japan. Transarterial chemoembolization failure/refractoriness: JSH-
LCSGJ criteria 2014 update. Oncology. 2014;87:22-31. DOI PubMed
22. Cheng AL, Amarapurkar D, Chao Y, et al. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma:
consensus recommendations and review by an International Expert Panel. Liver Int. 2014;34:174-83. DOI PubMed
23. Zhong B, Zhang S, Zhu H, Wang W, Ni C. ; Clinical Guidelines Committee of Chinese College of Interventionalists. Transarterial
chemoembolization refractoriness in hepatocellular carcinoma: Chinese College of Interventionalists definition and consensus statement.
Chin Med J 2024;137:2040-2. DOI PubMed PMC
24. Yang C, Luo YG, Yang HC, Yao ZH, Li X. Effects of early TACE refractoriness on survival in patients with hepatocellular carcinoma: a
real-world study. J Hepatocell Carcinoma. 2022;9:621-31. DOI PubMed PMC
25. Li BR, Zhang LO. Research progresses in molecular mechanisms of TACE resistance of hepatocellular carcinoma. Chin J Interv
Imaging Ther. 2025;22:425-8. (in Chinese). DOI
26. Zhang S, Wang WS, Zhong BY, Ni CF. Subsequent treatment after transarterial chemoembolization failure/refractoriness: a review
based on published evidence. J Clin Transl Hepatol. 2022;10:740-7. DOI PubMed PMC
27. Yu SCH, Chan L, Lee KF, et al. Ethiodized oil-based transarterial chemoembolization for hepatocellular carcinoma: randomized clinical
trial of anhydrous cisplatin suspension versus cisplatin emulsion. Radiology. 2025;317:e242982. DOI PubMed
28. Shang JN, Zhao ZW, Zheng X, et al. Clinical efficacy and safety of thermosensitive hydrogel in transcatheter arterial chemoembolization
for the treatmentof primary liver cancer. J Med Imaging 2025;35:83-6. (in Chinese). DOI
29. Ogasawara S, Chiba T, Ooka Y, et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to
transarterial chemoembolization. Oncology. 2014;87:330-41. DOI PubMed
30. Arizumi T, Ueshima K, Minami T, et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE)
refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer. 2015;4:253-62. DOI PubMed PMC
31. Alharbi SR. Selective angiographic roadmap analysis (SARA) of hepatocellular carcinoma feeding arteries for transarterial
chemoembolization. Diagnostics. 2025;15:2533. DOI PubMed PMC
32. Clinical Guidelines Committee of Chinese College of Interventionalists. [Chinese clinical practice guidelines for transarterial
interventions of hepatocellular carcinoma (2026 edition)]. Zhonghua Yi Xue Za Zhi. 2026;106:1998-2021. DOI PubMed
33. Wang K, Feng J, Yu H, et al. Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate
hepatocellular carcinoma: a single-arm, phase 2 trial. Signal Transduct Target Ther. 2025;10:328. DOI PubMed PMC
34. Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced
hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41:117-27. DOI PubMed
35. Li W, Lu M, Yuan G, et al. Comparison of the efficacy and safety of TACE-HAIC-MTTs-ICIs and TACE-MTTs-ICIs in the
hepatocellular carcinoma: a prognostic analysis based on the dynamic changes of serum AFP. Int J Surg. 2025;111:7041-52. DOI
PubMed PMC
